The Spanish Popular party has asked in the Spanish Congress that the number of high charges in Insalud be reduced and that an investment of just over 1 billion pesetas ($8 million) be cancelled, which would result in a saving of 2.1 billion pesetas in 1995.
This would compensate for the negative effect of the selective financing law (Marketletters passim) or go towards financing of new medicines, said a PP spokesperson at a press conference.
Meantime, Spain's General Council of Doctors has made an appeal for cessation before the Supreme Court against the High Court decision rejecting an appeal against the ministerial order that set up the selective financing of medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze